Qiagen (NYSE:QGEN) Shares Bought by Barclays PLC

Barclays PLC lifted its stake in shares of Qiagen (NYSE:QGEN - Free Report) by 170.6% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,849,004 shares of the company's stock after purchasing an additional 1,165,594 shares during the period. Barclays PLC owned 0.81% of Qiagen worth $84,259,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in QGEN. CWM LLC boosted its stake in Qiagen by 12.0% during the second quarter. CWM LLC now owns 2,505 shares of the company's stock worth $103,000 after buying an additional 269 shares during the period. Blue Trust Inc. boosted its stake in shares of Qiagen by 21.0% in the 2nd quarter. Blue Trust Inc. now owns 7,891 shares of the company's stock valued at $339,000 after buying an additional 1,369 shares during the period. Raymond James & Associates grew its position in shares of Qiagen by 12.7% during the second quarter. Raymond James & Associates now owns 542,453 shares of the company's stock worth $22,289,000 after buying an additional 61,008 shares in the last quarter. Mayfair Advisory Group LLC acquired a new position in shares of Qiagen during the second quarter worth about $268,000. Finally, Fifth Third Bancorp raised its holdings in Qiagen by 9.4% in the second quarter. Fifth Third Bancorp now owns 76,592 shares of the company's stock valued at $3,147,000 after acquiring an additional 6,573 shares in the last quarter. Institutional investors and hedge funds own 70.00% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on QGEN. Hsbc Global Res raised shares of Qiagen to a "hold" rating in a research report on Thursday, October 17th. Jefferies Financial Group reaffirmed a "buy" rating and set a $54.00 price objective (up from $42.00) on shares of Qiagen in a research report on Tuesday. Finally, HSBC cut Qiagen from a "buy" rating to a "hold" rating and set a $49.00 target price for the company. in a research note on Thursday, October 17th. Four investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $51.15.

Qiagen Stock Performance

Qiagen stock traded down $0.19 during midday trading on Thursday, hitting $45.97. 613,864 shares of the company's stock were exchanged, compared to its average volume of 1,137,470. Qiagen has a 12-month low of $39.03 and a 12-month high of $47.44. The stock has a market cap of $10.49 billion, a price-to-earnings ratio of 117.87, a price-to-earnings-growth ratio of 3.37 and a beta of 0.35. The firm's 50 day simple moving average is $43.18 and its 200 day simple moving average is $43.70. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.89 and a current ratio of 2.17.

Qiagen Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.